Literature DB >> 29847991

Activated naïve B cells promote development of malignant pleural effusion by differential regulation of TH1 and TH17 response.

Xiu-Zhi Wu1, Xin-Yu Shi1, Kan Zhai1, Feng-Shuang Yi1, Zhen Wang1, Wen Wang1, Xue-Bin Pei1, Li-Li Xu1, Zheng Wang1, Huan-Zhong Shi1.   

Abstract

Inflammatory signaling networks between tumor cells and immune cells contribute to the development of malignant pleural effusion (MPE). B cells have been found in MPE; however, little is known about their roles there. In the present study, by using mouse MPE models, we noted that although the total B cells in MPE were decreased as compared with the corresponding blood and spleen, the percentage of activated naïve B cells expressing higher levels of CD80, CD86, myosin heavy chain-II, CD44, CD69, and programmed cell death-ligand 1 (PD-L1) molecules were increased in wild-type mouse MPE. Compared with wild-type mice, decreased T helper (TH)1 cells and increased TH17 cells were present in B cell-deficient mouse MPE, which paralleled to the reduced MPE volume and longer survival time. Adoptive transfer of activated naïve B cells into B cell-deficient mice was able to increase TH1 cells and decrease TH17 cells in MPE and shorten the survival of mice bearing MPE. Furthermore, we demonstrated that activated naïve B cells inhibited TH17-cell expansion via the PD-1/PD-L1 pathway and promoted naïve CD4+ T-cell differentiation into TH1/TH17 cells through secreting IL-27/IL-6 independent of the PD-1/PD-L1 pathway. Collectively, our data uncovered a mechanism by which naïve B cells promote MPE formation by regulating TH1/TH17 cell responses, making these B cells an attractive target for therapeutic intervention in the fight against cancer.

Entities:  

Keywords:  B cells; TH cells; malignant pleural effusion

Mesh:

Substances:

Year:  2018        PMID: 29847991     DOI: 10.1152/ajplung.00120.2018

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  7 in total

Review 1.  Making cold malignant pleural effusions hot: driving novel immunotherapies.

Authors:  Pranav Murthy; Chigozirim N Ekeke; Kira L Russell; Samuel C Butler; Yue Wang; James D Luketich; Adam C Soloff; Rajeev Dhupar; Michael T Lotze
Journal:  Oncoimmunology       Date:  2019-01-22       Impact factor: 8.110

Review 2.  Th17 cells and their related cytokines: vital players in progression of malignant pleural effusion.

Authors:  Yiran Niu; Qiong Zhou
Journal:  Cell Mol Life Sci       Date:  2022-03-17       Impact factor: 9.261

3.  Autologous Splenocyte Reinfusion Improves Antibody-Mediated Immune Response to the 23-Valent Pneumococcal Polysaccharide-Based Vaccine in Splenectomized Mice.

Authors:  Shengwen Calvin Li; Mustafa H Kabeer
Journal:  Biomolecules       Date:  2020-05-01

4.  Single-cell analysis of diverse immune phenotypes in malignant pleural effusion.

Authors:  Zhong-Yin Huang; Ming-Ming Shao; Jian-Chu Zhang; Feng-Shuang Yi; Juan Du; Qiong Zhou; Feng-Yao Wu; Sha Li; Wei Li; Xian-Zhen Huang; Kan Zhai; Huan-Zhong Shi
Journal:  Nat Commun       Date:  2021-11-18       Impact factor: 14.919

5.  Effects of Molecular Iodine/Chemotherapy in the Immune Component of Breast Cancer Tumoral Microenvironment.

Authors:  Olga Cuenca-Micó; Evangelina Delgado-González; Brenda Anguiano; Felipe Vaca-Paniagua; Alejandra Medina-Rivera; Mauricio Rodríguez-Dorantes; Carmen Aceves
Journal:  Biomolecules       Date:  2021-10-12

Review 6.  Interleukin-27 and Its Diverse Effects on Bacterial Infections.

Authors:  Yugo Morita; Elysia A Masters; Edward M Schwarz; Gowrishankar Muthukrishnan
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

7.  Profiles of Immune Infiltration in Bladder Cancer and its Clinical Significance: an Integrative Genomic Analysis.

Authors:  Zonglong Wu; Kejia Zhu; Qinggang Liu; Yaxiao Liu; Lipeng Chen; Jianfeng Cui; Hongda Guo; Nan Zhou; Yaofeng Zhu; Yan Li; Benkang Shi
Journal:  Int J Med Sci       Date:  2020-03-05       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.